SCHEMBL44108

SCHEMBL44108

CCc1cc(CCNCc2ccc(C(C)(C)C)cc2)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
NR1I3 Q14994 1/20 0.45
ESRRB O95718 1/20 0.43
ESRRG P62508 1/20 0.43
CNR1 P21554 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 1/20 0.42
P4HB P07237 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
HDAC1 Q13547 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GPR84 Q9NQS5 1/20 0.40
EPHX2 P34913 1/20 0.40
NR1H4 Q96RI1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL43628 0.99 CA1 (0.52) CA1CA2NR1I3ESRRBESRRG
SCHEMBL3243483 0.86 NR1I3 (0.56) CA1CA2NR1I3ESRRBESRRG
Hydrochloric Acid SCHEMBL3950184 0.85 CYP1A2 (0.58) CA1CA2NR1I3ESRRBESRRG
SCHEMBL3947879 0.82 CA1 (0.51) CA1CA2NR1I3ESRRBESRRG
SCHEMBL3231014 0.82 CA1 (0.54) CA1CA2NR1I3ESRRBESRRG
SCHEMBL47358 0.81 L3MBTL1 (0.42) CA1CA2NR1I3L3MBTL1KDM4E
Hydrochloric Acid SCHEMBL3944196 0.81 CYP1A2 (0.51) CA1CA2NR1I3ESRRBESRRG
SCHEMBL3238587 0.80 CA1 (0.49) CA1CA2NR1I3ESRRBESRRG
SCHEMBL3272738 0.80 CA1 (0.49) CA1CA2NR1I3ESRRBESRRG
Hydrochloric Acid SCHEMBL44584 0.80 CYP1A2 (0.44) NR1I3L3MBTL1KDM4EP4HBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984322-B1 BENZAMIDE AND HETEROARENE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-09-26 EP disclosed
US-20110313196-A1 NOVEL PROCESS HOFFMANN-LA ROCHE, INC. 2011-12-22 US disclosed
US-20110313196-A1 NOVEL PROCESS HOFFMANN-LA ROCHE, INC. 2011-12-22 US disclosed
US-20110313196-A1 NOVEL PROCESS HOFFMANN-LA ROCHE, INC. 2011-12-22 US disclosed
WO-2011157670-A2 NOVEL PROCESS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-22 WO disclosed
WO-2011157670-A2 NOVEL PROCESS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313196-A1 NOVEL PROCESS CYP3A5, CYP3A4, GBA1 CA1 4361/4885CA2 1782/4885NR1I3 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.